ArticleCell2019
Widespread and Functional RNA Circularization in Localized Prostate Cancer.
Abstract read
In one paragraph
Article in Cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 278 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
278citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
278 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Global research landscape and emerging trends of non-coding RNAs in prostate cancer: a bibliometric analysis.Frontiers in pharmacology · 2024Pooled it
- The Emerging Role of Circular RNAs in Prostate Cancer: A Systematic Review.Frontiers in cell and developmental biology · 2021Pooled it
- The RNA cargo of plasma-derived extracellular vesicles in mCRPC patients captures cancer cells and tumor microenvironment signals.bioRxiv : the preprint server for biology · 2026Article
- Circ_0001495 promotes bladder cancer progression by regulating miR-1184 via MAPK signaling pathway.Molecular biology reports · 2026Article
- Circular RNA as emerging precision therapeutics: from RNA regulation to peptide translation.Precision clinical medicine · 2026Review
- Identification of non-canonical peptides with moPepGen.Nature biotechnology · 2026Article
- METTL3-based epitranscriptomic editing screening identifies functional mNature cancer · 2026Article
- Transcriptional and epigenetic reprogramming, lineage plasticity and therapy resistance in prostate cancer.Journal of the National Cancer Center · 2026Review
- Junction-targeting designs limit the application of CRISPR-Cas13d in circular RNA perturbation studies.Nucleic acids research · 2026Article
- Non-coding RNAs in tumor-educated platelets: emerging roles in cancer progression, biomarker discovery, and therapeutic targeting.Frontiers in oncology · 2026Review
- Advances in the Mechanism of ceRNA Regulation in Postoperative Cognitive Dysfunction.Current neuropharmacology · 2026Review
- Concordant RNA-protein evidence and human tissue metabolomics prioritize UPP1-associated nucleotide remodeling in prostate cancer.PloS one · 2026Article
- The Interaction ofInternational journal of biological sciences · 2026Article
- Review
- Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models.Molecular oncology · 2025Article
- HypoxamiRs in pancreatic cancer: master regulators of the hypoxic tumor microenvironment.Cell biology and toxicology · 2025Review
- Circular RNA profiling identifies circ_0001522, circ_0001278, and circ_0001801 as predictors of unfavorable prognosis and drivers of triple-negative breast cancer hallmarks.Cell death discovery · 2025Article
- Extracellular vesicle-mediated transmission of circPDLIM5 promotes lymphatic metastasis in prostate cancer.Journal of experimental & clinical cancer research : CR · 2025Article
- Chemically modified non-coding RNAs in cancer.Expert reviews in molecular medicine · 2025Review
- Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation.Cancer cell · 2025Article
218 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
49 authors.
Sujun ChenDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Vincent HuangOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Xin XuPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Julie LivingstoneOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Fraser SoaresPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Jouhyun JeonOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Yong ZengPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Junjie Tony HuaDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Jessica PetriccaDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Haiyang GuoPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Miranda WangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Fouad YousifOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Yuzhe ZhangPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; College of Life Sciences, Central China Normal University, Wuhan, Hubei, China; College of Basic Medical Sciences, Dali University, Dali, Yunnan, China.
Nilgun DonmezVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Musaddeque AhmedPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Stas VolikVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Anna LapukVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Melvin L K ChuaOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Lawrence E HeislerOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Adrien FoucalOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Natalie S FoxDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Michael FraserPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Vinayak BhandariDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Yu-Jia ShiahOntario Institute for Cancer Research, Toronto, Ontario, Canada.
Jiansheng GuanPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; College of Electrical Engineering and Automation, Xiamen University of Technology, Xiamen, China.
Jixi LiState Key Laboratory of Genetic Engineering, Department of Neurology, School of Life Sciences and Huashan Hospital, Fudan University, Shanghai, China.
Michèle OrainResearch Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
Valérie PicardResearch Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
Hélène HovingtonResearch Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
Alain BergeronResearch Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
Louis LacombeResearch Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
Yves FradetResearch Centre of CHU de Québec-Université Laval, Québec City, Québec, Canada.
Bernard TêtuSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Stanley LiuDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Radiation Oncology, Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada.
Felix FengDepartment of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA; Department of Urology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
Xue WuTranslational Medicine Research Institute, Geneseeq Technology, Toronto, Ontario, Canada.
Yang W ShaoTranslational Medicine Research Institute, Geneseeq Technology, Toronto, Ontario, Canada; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
Malgorzata A KomorTranslational Gastrointestinal Oncology, Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncoproteomics Laboratory, Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
Cenk SahinalpVancouver Prostate Centre, Vancouver, British Columbia, Canada.
Colin CollinsVancouver Prostate Centre, Vancouver, British Columbia, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Youri HoogstrateDepartment of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Mark de JongGenomeScan, Leiden, the Netherlands.
Remond J A FijnemanTranslational Gastrointestinal Oncology, Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Teng FeiCollege of Life and Health Sciences, Northeastern University, Shenyang, China.
Guido JensterDepartment of Urology, Erasmus Medical Centre, Rotterdam, the Netherlands.
Theodorus van der KwastPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.
Robert G BristowPrincess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada; Division of Cancer Sciences, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; Manchester Cancer Research Centre, Manchester, UK.
Paul C BoutrosDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Centre, University of California, Los Angeles, Los Angeles, CA, USA; Institute for Precision Health, University of California, Los Angeles, Los Angeles, CA, USA. Electronic address: pboutros@mednet.ucla.edu.
Housheng Hansen HeDepartment of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada. Electronic address: Hansenhe@uhnresearch.ca.
Funding
CIHR 142246CIHR 146586CIHR 152863CIHR 152864CIHR 159567
Abstract
The cancer transcriptome is remarkably complex, including low-abundance transcripts, many not polyadenylated. To fully characterize the transcriptome of localized prostate cancer, we performed ultra-deep total RNA-seq on 144 tumors with rich clinical annotation. This revealed a linear transcriptomic subtype associated with the aggressive intraductal carcinoma sub-histology and a fusion profile that differentiates localized from metastatic disease. Analysis of back-splicing events showed widespread RNA circularization, with the average tumor expressing 7,232 circular RNAs (circRNAs). The degree of circRNA production was correlated to disease progression in multiple patient cohorts. Loss-of-function screening identified 11.3% of highly abundant circRNAs as essential for cell proliferation; for ∼90% of these, their parental linear transcripts were not essential. Individual circRNAs can have distinct functions, with circCSNK1G3 promoting cell growth by interacting with miR-181. These data advocate for adoption of ultra-deep RNA-seq without poly-A selection to interrogate both linear and circular transcriptomes.
Indexed as
Gene Expression ProfilingGenetic ProfileHEK293 CellsHumansMaleMicroRNAsProstateProstatic NeoplasmsRNARNA, CircularRNA SplicingRNA, UntranslatedSequence Analysis, RNATranscriptomeMicroRNAsRNARNA, CircularRNA, Untranslatedbiomarkercircular RNAnon-coding RNAprostate cancerRNA-seqtranscriptome
Identifiers
PMID
30735634What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.